Retrophin Inc at Barclays Global Healthcare Conference Transcript
All right, we'll get started. I'm Scott Puckhaber, I'm the biopharmaceutical team here at Barclays. It's my pleasure to introduce Retrophin. And today, we have CEO, Eric Dube, with us.
So Eric, do you want to come up?
Thank you, Scott, and good afternoon, everyone, and thank you to Barclays for the opportunity to share an update on Retrophin with you today.
In my presentation, I'll be sharing some forward-looking statements, so you can look at our SEC filings for additional information.
I joined the company the beginning of this year, and I am proud to represent the over 200 employees at Retrophin who make it their life's work to identify, develop and deliver life-changing therapies for patients living with rare disease. And today, I'd like to share a little bit about the company and focus particularly on our pipeline. I believe that Retrophin offers a unique profile for a rare disease
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |